Health and Healthcare
Great News for Lung Cancer Patients in Spectrum’s Phase 2 Trial
Published:
Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) announced good news for cancer patients in its midstage trial on Tuesday. The company announced that it met the prespecified primary endpoint in the Zenith20 Phase 2 clinical trial evaluating poziotinib in previously treated non-small cell lung cancer patients with HER2 exon 20 insertion mutations.
The second cohort of the Zenith20 clinical trial enrolled 90 patients. They all had failed at least one line of prior systemic therapy, with 60 patients (67%) having failed two or more prior therapies, including chemotherapy and immunotherapy.
The intent-to-treat analysis demonstrated a confirmed objective response rate of 27.8% with a 95% confidence interval ranging from an objective response rate of 18.9% to 38.2%.
Based on the pre-specified statistical hypothesis for the primary endpoint, the observed lower bound of 18.9% exceeded the prespecified lower bound of 17% in this heavily pretreated population.
The median duration of response was 5.1 months with a median follow up of 8.3 months. The disease control rate was 70% and the median progression-free survival was 5.5 months.
Note that the second cohort was designed to be a registrational study, and Spectrum Pharma is in the process of requesting a meeting with the FDA to discuss this data and plans for a New Drug Application submission.
Spectrum Pharma stock was last seen up about 15% at $3.73, in a 52-week range of $1.74 to $10.57. The consensus price target is $9.00.
24/7 Wall St.100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
